3 terminated, 2 recruiting. 5 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Terminated 3, Recruiting 2 |
| Phase 2 | 3 | Terminated 2, Recruiting 1 |
Follow Metastatic Leiomyosarcoma: new trials by email Literature Review of Metastatic Leiomyosarcoma trials Research Report on Metastatic Leiomyosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma Abemaciclib, Biopsy Procedure, Biospecimen Collection - Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 74 | 2026-03-18 | 2026-10-21 |
| Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2024-02-06 | 2026-10-28 |
| Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas Itacitinib, Laboratory Biomarker Analysis - Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 27 | 2019-09-30 | 2024-05-08 |
| Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery Avelumab, Trabectedin - Metastatic Leiomyosarcoma, Metastatic Liposarcoma | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 35 | 2017-09-28 | 2022-04-29 |
| Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Pazopanib, Pazopanib Hydrochloride, Sapanisertib - High Grade Sarcoma, Metastatic Leiomyosarcoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 151 | 2015-11-30 | 2022-08-23 |
Leiomyosarcoma (5) · Histiocytoma, Malignant Fibrous (3) · Liposarcoma (3) · Sarcoma (3) · Sarcoma, Synovial (3) · Dermatofibrosarcoma (2) · Chondrosarcoma (1) · Liposarcoma, Myxoid (1) · Neurofibrosarcoma (1)
Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms, Connective and Soft Tissue (5) · Neoplasms, Muscle Tissue (5) · Neoplasms, Adipose Tissue (4) · Histiocytoma (3) · Neoplasms, Connective Tissue (3) · Neoplasms, Fibrous Tissue (3) · Fibrosarcoma (2) · Sarcoma (2) · Liposarcoma (1) · Neoplasms, Nerve Tissue (1) · Nerve Sheath Neoplasms (1) · Nervous System Diseases (1) · Nervous System Neoplasms (1)
Biopsy (2) · Specimen Handling (2) · Docetaxel (1) · Doxorubicin (1) · Gemcitabine (1) · INCB039110 (1) · Magnetic Resonance Spectroscopy (1) · Trabectedin (1) · abemaciclib (1) · avelumab (1) · baricitinib (1) · itacitinib (1) · liposomal doxorubicin (1) · pazopanib (1) · peposertib (1)
National Cancer Institute (NCI) (3) · Fred Hutchinson Cancer Center (2)
United States (5)
Candace L Haddox (1) · Elise F Nassif (1) · Lee Cranmer (1) · Seth Pollack (1) · William D Tap (1)
P30CA015704 (1), U10CA180821 (1), UM1CA186688 (1), UM1CA186709 (1)